Acumen Pharmaceuticals to Stop Sabirnetug Development in Alzheimer's After Phase 2 Trial Failure

07:42 AM EDT, 10/30/2026 (MT Newswires) -- Acumen Pharmaceuticals (ABOS) said Friday it plans to stop development of sabirnetug in Alzheimer's disease after its phase 2 trial failed to meet the primary goal of slowing cognitive and functional decline in patients with early-stage disease. The company said the trial also failed to meet key secondary goals, including measures of dementia severity, and sabirnetug did not show a significant benefit over placebo at either the 35 mg/kg or 50 mg/kg dose after 18 months. The company said it expects additional biomarker and imaging data in the coming weeks but does not believe the findings will change the trial's overall results. Acumen said it plans to discontinue clinical development, including the open-label extension portion of the trial, and explore strategic options, including for its Enhanced Brain Delivery program. Shares of the company were down more than 78% in Friday's premarket activity.